Imagine battling relentless fatigue, brain fog, and breathlessness long after a supposed recovery from COVID-19. For millions worldwide, this is the harsh reality of long COVID, a condition shrouded in mystery. But what if the root of this suffering isn't just the coronavirus itself? A groundbreaking review by 17 leading microbiologists, published in eLife, suggests that hidden infections might be the missing piece of this puzzling medical enigma.
Here’s the eye-opening twist: these experts, including Maria Laura Gennaro from Rutgers Health, argue that co-infections—those lurking alongside or triggered by SARS-CoV-2—could be silently prolonging symptoms for countless individuals. "This is an aspect of long COVID that doesn’t get nearly enough attention," Gennaro points out, highlighting a critical gap in our understanding.
Long COVID affects up to 400 million people globally, with symptoms ranging from mild discomfort to severe disability, impacting the brain, heart, lungs, and digestive system. Yet, despite its widespread impact, no proven treatments exist because the underlying causes remain elusive. This new review synthesizes existing research and expert insights to spotlight a largely overlooked theory: infections beyond COVID-19 could be key culprits.
And this is the part most people miss: One of the most compelling pieces of evidence points to the Epstein-Barr virus (EBV), the pathogen behind mononucleosis. Roughly 95% of adults carry latent EBV, often without symptoms—until something like COVID-19 disrupts the immune system, reactivating the dormant virus. Early studies found that two-thirds of long COVID patients showed signs of recent EBV activity, with higher antibody levels correlating to more severe symptoms. Later research linked EBV reactivation to hallmark long COVID symptoms like fatigue and cognitive issues.
But EBV isn’t the only suspect. Tuberculosis (TB), which affects a quarter of the global population in its latent form, could also play a role. COVID-19 appears to deplete the immune cells that keep TB in check, potentially triggering its reactivation. Conversely, TB infection might worsen COVID-19 outcomes, creating a dangerous two-way street.
But here’s where it gets controversial: The timing of these co-infections matters—a lot. Infections before COVID-19 could weaken the immune system, while those during acute illness might exacerbate tissue damage. Post-COVID infections could exploit lingering immune dysfunction. The researchers also introduce the concept of "immunity theft," suggesting that acute COVID-19 leaves individuals more vulnerable to other infections. This theory aligns with data from 44 nations, which have seen tenfold increases in at least 13 infectious diseases since the pandemic began.
If co-infections are indeed driving long COVID, there’s a silver lining: existing drugs like antibiotics and antivirals could be repurposed to target these underlying infections. Clinical trials could explore whether treating specific co-infections alleviates symptoms. However, the authors caution that their theory, while biologically plausible, remains speculative. "Correlation doesn’t equal causation," Gennaro reminds us, emphasizing the need for large-scale epidemiological studies and animal experiments—a challenge given the lack of reliable animal models for long COVID.
This review doesn’t offer immediate solutions for the millions suffering from long COVID, but it opens exciting new avenues for research. Perhaps, the authors suggest, effective treatment requires looking beyond COVID-19 itself. What do you think? Could hidden infections be the key to unlocking the long COVID mystery? Share your thoughts in the comments—let’s spark a conversation!
